Discovery of Pazopanib: A Pan Vascular Endothelial Growth Factor Kinase Inhibitor

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 57-77

  Harris, Philip A ^a   Stafford, Jeffrey A ^b  

^a GLAXOSMITHKLINE   (United States)

^b Takeda San Diego Inc   (United States)

Author keywords

Nonclinical toxicology; Pazopanib discovery pan vascular endothelial growth factor kinase inhibitor; Screening hits and structure based design

Indexed keywords

EID: 84889855663     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch3     Document Type: Chapter

References (31)

1. Altorki, N., Guarino, M., Lee, P., et al. (2008). Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): a proof-of-concept Phase II study. J Clin Oncol. 26, May 20 suppl; abstr 7557.
2. Baka, S., Clamp, A. R., and Jayson, G. C. (2006). A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis. Expert Opin Ther Targets. 10, 867-876.
3. Bamborough, P., Angell, R. M., Bhamra, I., et al. (2007). N-4-pyrimidinyl-1H-indazol-4-amine inhibitors of Lck: indazoles as phenol isosteres with improved pharmacokinetics . Bioorg Med Chem Lett. 17 (15), 4363-4368.
4. Bramson, H. N., Corona, J., Davis, S. T., et al. (2001). Oxindole-based inhibitors of cyclin-dependent kinase 2 (CDK2): design, synthesis, enzymatic activities, and X-ray crystallographic analysis. J Med Chem. 44, 4339-4358.
5. Caprioni, F., and Fornarini, G. (2007). Bevacizumab in the treatment of metastatic colorectal cancer. Future Oncol. 3, 141-148.
6. Carter, S. K. (2000). Clinical strategy for the development of angiogenesis inhibitors. Oncologist. 5 (Suppl. 1), 51-54.
7. Chabner, B. A., and Longo, D. L., Eds. (2005). Cancer Chemotherapy and Biotherapy:Principles and Practice, 4th Edition. Philadelphia: Lippincott Williams & Wilkins.
8. Chow, L. Q. M., and Eckhardt, S. G. (2007). Sunitinib: from rational design to clinical efficacy. J Clin Oncol. 25, 884-896.
9. Dev, I. K., Dornsife, R. E., Hopper T. M., et al. (2004). Antitumor efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumor models. Br J Cancer. 91, 1391-1398.
10. Folkman, J. (2007). Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov. 6, 273-286.
11. Fong, T. A. T., Shawver, L. K., Sun, L., et al. (1999). SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res. 59, 99-106.
12. Friedlander, M., Hancock, K. C., Benigno, B., et al. (2007). Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a Phase II study. J Clin Oncol. 25 (18 S), 5561.
13. Harris, P. A., Cheung, M., Hunter, R. N. III, et al. (2005). Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 48, 1610-1619.
14. Huh, J.-I., Calvo, A., Stafford, J., et al. (2005). Inhibition of VEGF receptors signifi-cantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanism. Oncogene. 24, 790-800.
15. Hutson, T. E., Davis, I. D., Machiels, J. H., et al. (2008). Biomarker analysis and final efficacy and safety results of a Phase II renal cell carcinoma trial with pazopanib (GW786034), a multi-kinase angiogenesis inhibitor. J Clin Oncol. 26, May 20 suppl; abstr 5046.
16. Hurwitz, H., Dowlati, A., Savage, S., et al. (2005). Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol. 23 (16 S), 3012.
17. Kane, R. C., Farrell, A. T., Saber, H., et al. (2006). Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res. 12, 7271-7278.
18. Karaman, M. W., Herrgard, S., Treiber, D. K., et al. (2008). A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 26, 127-132.
19. Kumar, R., Miller, C. G., Johnson, J. H., et al. (2003). Discovery and biological evaluation of GW654652: A pan inhibitor of VEGF receptors. Proc Amer Assoc Cancer Res. 44, 9 (abstract #39).
20. Kumar, R., Knick, V. B., Rudolph, S. K., et al. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multi-kinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Mol Cancer Ther. 6, 2012-2021.
21. Lantry, L. E. (2007). Drug evaluation: ranibizumab, a mAb against VEGF-A for the potential treatment of age-related macular degeneration and other ocular complications . Curr Opin Mol Ther. 9, 592-602.
22. Miwatashi, S., Arikawa, Y., Kotani, E., et al. (2005). Novel inhibitor of p38 MAP kinase as an anti-TNF α drug: discovery of N-[4-[2-ethyl-4-(3-methylphenyl)-1,3-thiazol-5-yl]-2-pyridyl]benzamide (TAK-715) as a potent and orally active anti-rheumatoid arthritis agent. J Med Chem. 48, 5966-5979.
23. O'Reilly, M. S., Boehm, T., Shing, Y., et al. (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 88, 277-285.
24. Pargellis, C., Tong, L., Churchill, L., et al. (2002). Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Structural Biol. 9 (4), 268-272.
25. Ramalingam, S., and Belani, C. P. (2007). Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncol. 3, 131-139.
26. Rogerson, T. D., Wilkinson, C. F., and Hetarski, K. (1977). Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem Pharmacol. 26, 1039-1042.
27. Sleijfer, S., Papai, Z., Cesne, A. Le, et al., (2007). Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS):EORTC 62043. J Clin Oncol. 25 (18 S), 10031.
28. Sorbera, L. A., Bolos, J., and Serradell, N. (2006). Pazopanib hydrochloride. Oncolytic, angiogenesis inhibitor, VEGFR-2 tyrosine kinase inhibitor. Drug Future. 31, 585-589.
29. Sonpavde, G., and Hutson, T. E. (2007). Pazopanib: a novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep. 9, 115-119.
30. Veber, D. F., Johnson, S. R., Cheng, H.-Y., et al. (2002). Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem. 45, 2615-2623.
31. Veikkola, T., Karkkainen, M., Claesson-Welsh, L., et al. (2000). Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 60, 203-212.